53039-48-8

Basic information

• Product Name: Benzene, 1-bromo-4-[(4-methoxyphenyl)methyl]-
• CAS NO: 53039-48-8
• Molecular Formula: C14H13BrO
• Molecular Weight: 277.161
• Mol File: 53039-48-8.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Benzene, 1-bromo-4-[(4-methoxyphenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-bromo-4-[(4-methoxyphenyl)methyl]-(53039-48-8)
• EPA Substance Registry System: Benzene, 1-bromo-4-[(4-methoxyphenyl)methyl]-(53039-48-8)

Safety Data

• Hazardous Substances Data: 53039-48-8(Hazardous Substances Data)

Upstream product

• 100-66-3 methoxybenzene 
• 586-76-5 4-Bromobenzoic acid 
• 5720-07-0 4-methoxyphenylboronic acid 
• 589-17-3 p-bromobenzyl chloride 
• 873-75-6 4-bromobenzenemethanol 
• 237763-11-0 methanesulfonic acid 4-bromo-benzyl ester 
• 33397-21-6 tris(4-methoxyphenyl)bismuth 
• 55883-45-9 4-bromobenzyliodide 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 36176-90-6 N-(4-bromobenzylidene)-4-methylbenzenesulfonamide 
• 10504-96-8 N-[(4-bromophenyl)methyl]-4-methylbenzenesulfonamide 
• 1333226-10-0 N,N-ditosyl-4-bromobenzylamine 
• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 54118-75-1 4-bromo-4'-methoxybenzophenone 

Downstream Products

• 109876-15-5 4-(4-Methoxy-benzyl)-benzenesulfonyl chloride 
• 181207-53-4 N-tert-butoxycarbonyl-4-[4-(4-methoxyphenyl)methylphenyl]-4-piperidinol 
• 855358-62-2 4-(4-bromo-benzyl)-phenol 

Relevant articles and documents

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

Synthetic method of diarylmethanes

The invention discloses a synthetic method of diarylmethanes. The method is characterized in that benzyl pseudohalide and aromatic boric acid are reacted in an organic solvent under alkaline condition. The method employs easily available raw materials, conversion is realized under effect of no transition metal catalysis, water-free and oxygen-free are not required, Lewis acid catalysis is not required, the method has wide substrate universality, and various substituted diarylmethanes can be synthesized by the method.

Threefold and chemoselective couplings of triarylbismuths with benzylic chlorides and iodides using palladium catalysis

This paper describes the palladium-catalyzed studies on threefold coupling of triarylbismuth reagents with benzylic chlorides and iodides. The optimized protocol conditions are operationally simple, delivering threefold coupling of a variety of triarylbismuths in combination with benzylic chlorides and iodides. The two optimized protocols allowed the synthesis of a diverse range of unsymmetrical diarylmethanes in an efficient manner. As part of this study, chemoselective transformation of benzylic chlorides and iodides was also achieved. This journal is the Partner Organisations 2014.